Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

  • Pages:
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Dec, 2017
  • SKU: DISR0015
  • Single User License
    (20% Off)
    $3,250.00
  • Site License
    (30% Off)
    $6,500.00
  • Global License
    (40% Off)
    $9,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's, "Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017" report provides comprehensive insights of the ongoing therapeutic research and development across mechanism of action.

Executive Summary

Overview

Competitive Landscape

Collaboration

Technology

Designation

Active Pipeline coverage by Indication

Marketed and Pipeline Drugs

Marketed Drug Profiles

Farydak: Novartis

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Farydak Global Sales

Farydak Analyst Insights

Beleodaq: Spectrum Pharmaceuticals

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Beleodaq Global Sales

Beleodaq Analyst Insights

Epidaza: Chipscreen Bioscience

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Epidaza Analyst Insights

Zolinza: Merck

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Zolinza Global Sales

Zolinza Analyst Insights

Istodax: Gloucester Pharmaceuticals

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Istodax Global Sales

Istodax Analyst Insights

Market Positioning of HDAC Inhibitors

HDAC Inhibitors Market Evaluation

HDAC Inhibitors Class Share Evaluation

Pipeline Therapeutics

Comparative Analysis

Late Stage Products (Phase III)

Comparative Analysis

Entinostat: Syndax Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Pracinostat: MEI Pharma

Product Description

Research and Development

Product Development Activities

Givinostat: Italfarmaco

Product Description

Research and Development

Product Development Activities

Mid-Stage Products (Phase II)

Comparative Analysis

Mocetinostat: Mirati Therapeutic

Product Description

Research and Development

Product Development Activities

Quisinostat: Janssen

Product Description

Research and Development

Product Development Activities

VRx-3996: Viracta Therapeutics

Product Description

Research and Development

Product Development Activities

Sulforadex: Evgen Pharma

Product Description

Research and Development

Product Development Activities

CHR 5154: Chroma Therapeutics

Product Description

Research and Development

Product Development Activities

CUDC 907: Curis

Product Description

Research and Development

Product Development Activities

Ricolinostat: Celgene Corporation

Product Description

Research and Development

Product Development Activities

Remetinostat: TetraLogic Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Abexinostat: Celera Genomics Group

Product Description

Research and Development

Product Development Activities

Resminostat: 4SC

Product Description

Research and Development

Product Development Activities

FRM 0334: FORUM Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Early Stage Products (Phase I)

Comparative Analysis

Citarinostat: Celgene Corporation

Product Description

Research and Development

Product Development Activities

AR-42: Arno Therapeutics

Product Description

Research and Development

Product Development Activities

EDO S101: Mundipharma International

Product Description

Research and Development

Product Development Activities

Pre-clinical Products

Comparative Analysis

PCI-34051: Pharmacyclics

Product Description

Research and Development

Product Development Activities

HG 3001: HitGen

Product Description

Research and Development

Product Development Activities

CG-1255: CircaGen Pharmaceutical

Product Description

Research and Development

Product Development Activities

CG-1521: CircaGen Pharmaceutical

Product Description

Research and Development

Product Development Activities

Trichostatin A: Errant Gene Therapeutics

Product Description

Research and Development

Product Development Activities

QTX-125: Quimatryx

Product Description

Research and Development

Product Development Activities

QTX-153: Quimatryx

Product Description

Research and Development

Product Development Activities

ACY 1083: Regenacy Pharmaceuticals

Product Description

Research and Development

Product Development Activities

ACY-738: Celgene Corporation

Product Description

Research and Development

Product Development Activities

Therapeutic Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Institutional Products

Inactive Products

Comparative Analysis

Market Drivers and Barriers

Appendix

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Table 1: Active Pipeline Coverage by Indication 
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors 
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration 
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type 
Table 12: Dormant Products
Table 13: Discontinued Products

Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II) 
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration 
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.